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Fátima Sousa2, Fátima Cerqueira4,5,6, Eugénia Pinto6,7,9 & Miguel Pais‑Vieira8,9*
Onychomycosis or tinea unguium (EE12.1) and Onychomycosis due to non‑dermatophyte moulds 
(1F2D.5) (OM) is a fungal infection of the nail plates with a high prevalence that often affects 
vulnerable people with co‑existing health problems. Gold standard pharmacological treatments for 
onychomycosis have been associated with low success rates and increasing antifungal resistance, 
suggesting that treatment outcome is dependent on multiple variables. Here, the prevalence of 
OM and quality of life were characterized in two vulnerable populations—Hospital patients and 
Homeless people. Comparing both groups, the most prevalent fungal species were identified 
in Hospital patients. Then, the in vitro fungicidal properties of the antiseptics povidone‑iodine, 
polyhexamethylene biguanide‑betaine, octenidine dihydrochloride, and a super‑oxidized solution 
against two ATCC strains (Candida albicans and Aspergillus niger) and three clinical fungal isolates 
from Hospital patients (Candida parapsilosis, Trichophyton interdigitale, and Trichophyton rubrum) 
were tested. OM prevalence was high in both patient groups studied, who also reported a reduction 
in quality of life and concerns about the state of their feet. In addition, Hospital patients had a non‑
negligent therapeutic regimen management style. Antiseptics tested in vitro revealed antifungal 
properties. As antiseptics are low‑cost and easy to apply and have few iatrogenic effects, the 
demonstration of fungicidal properties of these solutions suggests that they may constitute potential 
supportive therapeutics for OM.
Onychomycosis (OM) is a fungal infection of the nails plates that is often caused by dermatophytes and is charac-
terized by nail plate thickening and dystrophy. OM is estimated to infect 8.9% (95% CI 4.3–13.6) of the population 
in  Europe1. Epidemiological studies have indicated that the OM prevalence tends to be higher in older people 
and vulnerable  populations2. Some studies have revealed prevalence rates of 46% in diabetic patients with nail 
plate  problems3 and 51.3% in those that do not practice daily hygiene targeting the  feet4. In addition, patients 
with peripheral vascular disease are at increased risk of  onychomycosis5. The dermatophyte most frequently 
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identified in OM is Trichophyton rubrum followed by Trichophyton mentagrophytes6,7. However, several studies 
have also reported OM with non-dermatophyte  moulds8,9.
Currently, several treatments for OM are used, namely, laser treatment, surgery, debridement, and pharmaco-
logical  interventions10–12. The gold standard pharmacological treatment for OM is a continuous or intermittent 
therapeutic scheme including amorolfine, ciclopirox, terbinafine, and  itraconazole2,6,13. Despite the multiple 
approaches and treatments available, the success rate remains relatively  low13, with infection recurrence rates 
ranging from 40–70%13. Recent studies have suggested that this low success rate and the recurrence of infection 
may be, in part, explained by the iatrogenic effects of medication, long duration the treatment, associated cost, 
and self-care commitment and  style13. These studies have also suggested that approaches with fewer iatrogenic 
effects, which can reduce treatment length and expenses or promote self-care, may have the potential to improve 
current treatments and recurrence success rates. One group of substances with several of these characteristics 
are antiseptic solutions. These are inexpensive, generally well tolerated, and can be easily applied at home with-
out significant associated health risks. However, there is relatively scarce evidence on their efficacy in  OM14. To 
improve our current knowledge on the potential of antiseptic solutions as supportive therapies for OM treatment, 
four common antiseptics were tested against the dermatophyte, non-dermatophyte, and yeasts causative agents 
of OM. Testing this hypothesis requires a determination of which fungal species and antiseptic solutions should 
be studied while accounting for complex variables that have been previously demonstrated to influence the 
outcome of other treatments, namely, quality of life (QOL) and therapeutic regimen management style (TRMS).
To achieve this goal, we performed a three-part study to (i) characterize the prevalence of OM among patients 
from two groups (Hospital patients and Homeless people) and identify the most prevalent fungal species in Hos-
pital patients; (ii) characterize self-care and QOL in both groups and TRMS in Hospital patients; and (iii) evaluate 
in vitro the fungicidal properties of antiseptics often used in clinical practice for infected wounds: povidone-
iodine (PVP-I), polyhexamethylene biguanide-betaine (PHMB-B), octenidine dihydrochloride (OCT-D), and a 
super-oxidized solution (SOS) against two ATCC strains (Candida albicans and Aspergillus niger) and three clini-
cal isolates from Hospital patients (Candida parapsilosis, Trichophyton interdigitale and Trichophyton rubrum).
Methods
Sampling, OM prevalence and identification of the etiological agents. A general Hospital popu-
lation (Hospital Patients Group—HosPG) and a Homeless population (Homeless People Group—HomPG) were 
studied. The STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) checklist was 
used to report the  results15. All methods were performed in accordance with the relevant guidelines and regula-
tions. Statistical analysis was performed using IBM SPSS Statistics for Macintosh, Version 26.0. Armonk, NY: 
IBM Corp. (https:// www. ibm. com/ analy tics/ spss- stati stics- softw are).
The screening protocol for the HosPG and HomPG is presented in Fig. 1.
Hospital patients group. A descriptive, cross-sectional study was performed between September 2018 and 
December 2019 to evaluate the prevalence of OM in the HosPG. A nonprobability convenience sample compris-
ing ninety participants (Fig. 1) was enrolled. This observational study started with the initial referral of patients 
from specific departments (dermatology, endocrinology, podology, and internal medicine) who presented clini-
cal signs of OM (nail plate thickening, yellowing, and dystrophy). Participants were contacted subsequently 
referral from these departments, after initial screening by a Physician, a Dermatologist, a Nurse expert, or a 
Podiatrist. The inclusion criteria were as follows: 18 years of age or older, no obvious cognitive impairment, and 
clinical signs suggestive of OM. Sociodemographic characteristics, clinical history, and signs and symptoms 
related to OM were annotated and later analysed for each patient.
In all patients, feet were initially washed with mild soap and water, followed by antisepsis of the skin and 
nail plates with an alcoholic solution (70% v/v). Nail plates were then scraped with a sterile scalpel blade, and 
collected in a sterile container and sent to the laboratory. All samples were analyzed by direct microscopy and 
cultivable methods. Direct examination was performed based on microscopic preparations with 10–20% KOH 
and fungal cultivation on Sabouraud gentamicin chloramphenicol 2 (SGC2) and Sabouraud agar with chloram-
phenicol and cycloheximide. From positive culture, the present fungi were isolated and identified (in each case, 
pure cultures were obtained finally). Filamentous fungi, such as dermatophytes, were identified by macroscopic 
and microscopic observations, and yeasts were identified by a  VITEK® 2 Compact platform.
Diagnosis of dermatomycoses was based on the detection of septate hyphae by direct microscopic examina-
tion and cultivable methods with subcultures that were validated by two different pathologists. These analyses 
consisted of observation of morphology (pigmentation of the surface and reverse sides, topography, texture 
and rate of growth) and microscopic characteristics (size and shape of macroconidia and microconidia, spirals, 
nodular organs) in combination with biochemical and physiological tests (nutritional requirements, temperature 
tolerance, enzyme production). When an accurate identification could not be made using these methods, the 
samples were sent to a collaborating university hospital (Centro Hospitalar Universitário do Porto, Portugal) 
to be confirmed with an additional combination of methods, namely: urea broth, bromocresol purple agar, 
trichophyton agar. In addition, matrix-assisted laser desorption ionization-time of flight mass spectrometry 
(MALDI-TOF MS) was used to confirm the accurate identification of the isolates.
Homeless people group. A descriptive, cross-sectional study was performed between October 2018 and May 
2019 to define the prevalence of OM in the HomPG. The study population consisted of a nonprobability conven-
ience sample comprising fifty participants (Fig. 1). In the present research, we chose a convenience sample from 
an institution attended by Homeless people because it was essential to approach people without changing their 
quotidian routine. The study was conducted during lunch time (i.e., when Homeless people went to the institu-
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tion for a free meal). One researcher contacted and kept track of participants who met the inclusion criteria 
(same as those for the HosPG). Those who were selected to join the study were provided a detailed explanation, 
and signed informed consent was provided. For those who agreed to participate, health care and comfortable 
foot care were provided. Foot care consisted of washing the feet with a soap solution, followed by cleaning and 
disinfection with alcoholic solution. Then, a nail plate sample was collected, and a dermatophyte test (Diafactory 
Tinea Unguium, Japan) based on immunochromatography was immediately performed. This is a quick method 
that uses mouse monoclonal antibodies on a nitrocellulose membrane and which has a high sensitivity for der-
matophyte fungi (98.0%) and limited sensitivity for non-dermatophyte fungi (specificity, 88.2%). Nail plate sam-
ples were collected to a test tube and allowed to react for a period of 5 min. The final colour present in the test 
tube was then compared with the test strip. During this contact time, notes were taken on the characteristics of 
acute and chronic injuries, and participants’ biographic and health data were collected.
QOL and therapeutic regimen compliance. In part two of the study, the impact of OM on QOL was 
evaluated in a group of HosPG and HomPG patients. In the HosPG, therapeutic regimen compliance was evalu-
ated using the TRMS questionnaire with a grounded theory approach (explanatory theory on self-management 
in chronic illness)16. This self-report is composed of two parts. The first uses a scale ranging from 0—totally 
disagree to 4—totally agree and allows the identification of personality traits and attitudes towards the disease 
and the therapeutic regimen. The second part contains a scale ranging from 0—never to 4—always to evaluate 
the subjects’ perceived behaviour towards the therapeutic regimen.
Evaluation of fungicidal potential of antiseptic products. Fungicidal activity was evaluated accord-
ing to the European Standard EN 1275 “Chemical disinfectants and antiseptics—“Quantitative suspension test 
for the evaluation of basic fungicidal or basic yeasticidal activity of chemical disinfectants and antiseptics”17. This 
standard allows the testing of the fungicidal activity of antiseptic products when diluted with water and a neu-
tralizing formula. The common commercial antiseptic solutions PVP-I, PHMB-B, OCT-D, and SOS were tested 
at the highest concentration of 80%, diluted with water and added to a test fungal suspension. The obligatory 
test conditions required maintaining the mixture at 20 ± 1 °C under 15 min ± 10 s. Furthermore, this standard 
required the reference strains C. albicans ATCC 10231 and A. niger ATCC 16404 to evaluate fungicidal activ-
ity. In addition to testing under the standard conditions using the mandatory microorganisms indicated by EN 
1275, the fungicidal activity was also evaluated against the clinical isolates C. parapsilosis (FF179), T. interdigitale 
(FF164), and T. rubrum (FF165), which were the most prevalent fungal species isolated from the HosPG.
The SOS was tested as 95% solution due to the quick loss of properties when the solution was open. The 
neutralizer used was D/E neutralizing broth (NCM0047), which offered stability for all the antiseptics.
Figure 1.  Hospital Patients Group (HosPG) and Homeless People Group (HomPG) flow diagram.
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The numbers of CFUs (colony forming units) after treatment under test conditions were counted, and the 
log reduction was calculated. Following the EN 1275 recommendations, only when the reduction in CFUs was 
equal to or higher than log 4 was fungicidal activity considered.
Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS), version 26.0. The 
data are expressed as frequencies and percentages. Results were considered significant at an alpha value of 5%. 
The log reduction was calculated according to the formula described in EN  127517, i.e., as the log reduction dif-
ference between the number of CFU/ml test suspensions and the number of CFU/ml experimental suspensions.
Ethics approval. This study was approved by the Ethics Committee of the Universidade Católica Portu-
guesa, Centro de Investigação Interdisciplinar em Saúde [CE.C. (11)2018)] and the Ethics Committee of Armed 
Forces Hospital (SEFT-Estudos-0002/2017-1). Informed consent was signed by all the participants after careful 
explanation of the study. Subjects participated in the study at no cost. Confidentiality and privacy of participants’ 
personal data was guaranteed at all times according to the European Union General Data Protection Regulation 
2016/679.
Results
As the present study comprised multiple parts, the results will be presented as follows: (i) comparison of demo-
graphic and clinical history data of the HosPG and a HomPG; (ii) OM classification for both groups studied; (iii) 
description of QOL and TRMS in the HosPG; (iv) comparison between results obtained by direct examination 
in 10–20% KOH and based on cultivable methods in the HosPG and the results of quick dermatophyte tests in 
the HomPG; (v), comparisons of in vitro antifungal properties of antiseptics against three strains of the most 
prevalent yeast and dermatophyte species isolated from the HosPG (the summary of all the results are presented 
in Fig. 2.
Demographics of the hospital patients group and homeless people group. Table 1 shows the 
demographic and clinical data obtained in the prevalence study of the HosPG and HomPG. A total of 105 
patients from the general Hospital population were screened, and 85.7% (n = 90) presented clinical signs of OM. 
Moreover, among the Homeless population, a total of 120 people were screened, of which 41.7% (n = 50) were 
enrolled and constituted the HomPG.
EN 1275, in vitro
Sub-sample of patients (n=56) 
• KOH/Culture test: 53.3% (48/90)*
• Dermatophytes:  55.6% (40/72) 
• Trichophyton rubrum: 67.5% (27/40)
• Onychomycosis >5 years: 54.4% (49/90) 
• Self-care difficulties: 74.4% (67/90)
• Need caregiver: 65.6% (59/90)
• Embarrassment: 37.8% (34/90)
• Worry: 66.7% (60/90)
Non-negligent style
Responsible: 12·5% (7/56)
Undefined style: 87·5%  (49/56)
Hospital Patients Group (HosPG)
(n=90) 
Homeless People Group (HomPG)
(n=50) 
• Quick dermatophyte test: 82.0% (41/50)
• Onychomycosis >5 years: 40.0% (20/50)
• Self-care difficulties: 48.0% (24/50)
• Need caregiver: 59.2% (35/50)
• Embarrassment: 54.0% (27/50)







* Some patients had more than one fungal species isolated
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Onychomycosis classification. The most prevalent pattern in the HosPG was the mixed pattern (21.4%; 
191/894 toenails observed), followed by Distal and Lateral Subungual Onychomycosis (DLSO) (20.6%, 184/894). 
Total Dystrophy Onychomycosis (TDO) (2.7%; 24/894), Superficial White Onychomycosis (1.0%; 9/894), and the 
Proximal Subungual Onychomycosis (0.7%; 6/894) were less prevalent. Slightly more than half of the toenails 
(54.4%, 486/894) presented no alterations.
In the HomPG, the main pattern was DLSO (49.9%; 249/499 toenails observed), followed by the Mixed Pat-
tern Onychomycosis (12.8%, 64/499) and TDO (3.8%, 19/499). One-third of the nails plates (33.1%; 165/499) 
presented no alterations. The DLSO pattern was observed in all nails plates, particularly in the first toenail (hal-
lux) (68.0%, 34/50 right foot; 64.0%, 32/50 left foot). The 5th toenail presented the most heterogeneous patterns. 
These patterns occurred symmetrically in both feet, with minimal differences between the right and left foot. 
In addition, many participants (68.0%; 34/50) had between three and five nails plates affected on each foot. No 
differences were found between the right and left foot (p = 0.59).
Table 1.  Demographic and clinical data of the Homeless People Group (HomPG) and Hospital Patients Group 
(HosPG). Data are n (%). HomPG Hospital Patients Group, HosPG Homeless People Group.
HomPG HosPG
Age group at registration (years) n = 50 n = 90
Mean (SD) 53 (11.1) 65 (15.4)
≥ 18 ≤ 40 3 (6%) 7 (8%)
> 40 ≤ 60 34 (68%) 22 (24%)
> 60 13 (26%) 61 (68%)
Sex n = 50 n = 90
Female 8 (16%) 32 (36%)
Male 42 (84%) 58 (64%)
Education
Basic education first cycle 29 (58%) 38 (42%)
Basic education second and third cycle 13 (26%) 17 (19%)
Secondary education 5 (10%) 25 (28%)
Higher education 3 (6%) 10 (11%)
Clinical history (number of factors) n = 113 n = 165
Oncological disease 1 (1%) 13 (8%)
Visual or hearing disability 5 (4%) 5 (3%)
Psychiatric disorder 5 (3%) 3 (2%)
Accidents/trauma 7 (6%) 2 (1%)
Surgical history 7 (6%) 30 (18%)
Chronic disease 11 (10%) 28 (17%)
Cardio and cerebrovascular disease 13 (12%) 58 (35%)
Commitment to mobility and self-care 13 (12%) 10 (6%)
Infectious disease 21 (19%) 12 (7%)
Addiction (alcohol, tobacco, drugs) 30 (27%) 3 (2%)
Signs and symptoms of onychomycosis n = 50 n = 90
Pain 30 (60%) 32 (36%)
Soreness 37 (74%) 59 (66%)
Injury 40 (80%) 27 (30%)
Thickening 46 (92%) 81 (90%)
Yellowing/discolouration 50 (100%) 90 (100%)
Impact on quality of life n = 50 n = 90
Daily hygiene for feet 14 (28%) 66 (73%)
Caregiver needed 15 (30%) 59 (66%)
Self-care difficulties 24 (48%) 67 (74%)
Use changing rooms or swimming pools 25 (50%) 9 (10%)
Shame/embarrassment 27 (54%) 34 (38%)
Worry 34 (68%) 60 (67%)
Wearing inadequate footwear 50 (100%) 8 (9%)
Onychomycosis prevalence n = 50 n = 90
Positive dermatophytes test 41 (82%) –
Laboratory diagnosis (KOH + culture) – 48 (53%)
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QOL in patients suffering of onychomycosis. Analysis of the QOL indicated that for 73.3% (66/90) of 
the subjects in the HosPG, foot hygiene was part of their daily routine. Close to 65% reported needing help from 
a caregiver to perform daily hygiene activities (59/90), and 74.4% reported having self-care difficulties (67/90). 
Shame or embarrassment was reported by 37.8% (34/90), with 66.7% (60/90) reporting being worried about the 
condition of their feet.
In the HomPG, foot hygiene was not part of their daily routine (72.0%; 36/50), with 70.0% (35/50) indicating 
that they needed help from a caregiver to perform daily hygiene activities. Slightly less than half of the subjects 
(48.0%, 24/50) reported having self-care difficulties. Furthermore, 54.0% (27/50) reported shame or embarrass-
ment, and 68.0% (34/50) reported being worried about the condition of their feet.
When questioned about the duration of their OM, the majority of the respondents in the HosPG reported 
that their OM had been present for longer than 5 years (54.4%, 49/90), while 8.9% (8/90) did not know or did 
not answer. In the HomPG, 28.0% (14/50) did not know or did not answer the question regarding foot hygiene 
frequency and reported that their OM had been present for longer than 5 years.
These results indicated that the prevalence of OM was high and had been present for several years in both 
groups of patients. Subjects had self-care difficulties and were worried about the condition of their feet; therefore, 
their QOL was compromised.
Non‑negligent therapeutic regimen management. To gain further knowledge about the possible 
causes of the low success rate of current OM treatments, the Questionnaire on Personality Traits and Attitudes 
Towards the Disease and the Therapeutic  Regimen14 was administered to 62.2% (56/90) of the HosPG. The 
majority of participants presented an undefined style (85.7%, 48/56), and 14.3% (8/56) were classified as responsi-
ble (i.e., involving the constructs of control and flexibility). Even though a clear style could not be defined for the 
majority of the subjects, the characteristics of rigidity and temptation, which are more often associated with the 
negligent type, were largely absent in this subsample. This multivariable deviation from the negligent character-
istics can be observed in the radar chart presented in Fig. 3. These results indicated that the sub-sample analysed 
was mostly characterized by a non-negligent regimen management style.
Detection of fungi in clinical materials and identification of isolates to the species level. A 
total of 90 HosPG samples were collected and analysed by direct microscopy and cultivable methods; a positive 
result of direct microscopical examination of nail plate samples was present in 52.2% (47/90) and 53.3% (48/90) 
in case of founded fungal cultures. Among the 72 fungal isolates obtained by mycological cultures on Sabouraud 
agar 55.6% (40/72) were dermatophytes. T. rubrum was the most common fungal species isolated from these 
samples, at 37.5% (27/72 isolates), and the most frequently isolated dermatophyte, at 27/40 (67.5%) (Table 2).
The diagnosis of OM in the HomPG with a kit dermatophytes test revealed that out of the fifty participants 
with clinical signs of tinea unguium, 82.0% (41/50) had a positive test result.
In vitro antifungal activity of antiseptics. As OM had a high prevalence and was associated with a 
reduction in QOL (in the both studied groups of patients) and with a non-negligent therapeutic regimen style 
(in the HosPG), whether antiseptic solutions have potential as a simple and safe co-adjuvant treatment for OM 
was considered. For this, the in vitro effects of different antiseptic solutions were tested against the ATCC strains 
and the three most prevalent fungal species identified in the group of HosPS patients.
European Standard EN 1275 was followed for testing commercial formulas of PVP-I, PHMB-B, OCT-D, and 
SOS. The results obtained after  log10 reduction (logR) are presented in Table 3.
Figure 3.  Chart of the TRMSs of patients with OM.
7
Vol.:(0123456789)
Scientific Reports |        (2021) 11:12789  | https://doi.org/10.1038/s41598-021-92111-4
www.nature.com/scientificreports/
Considering the reference strains of fungi used for the test validation, for A. niger, we verified a  log10 reduction 
in antiseptic activity less than 4 (logR = 3.10 ± 0.10), indicating that no fungicidal activity for the four antisep-
tics could be detected according to EN 1275. However, for C. albicans, fungicidal activity was found for PVP-I, 
PHMB-B, and OCT (logR = 4.39 ± 0.12). For this species, the SOS did not produce consistent results, with the 
three valid tests indicating a mean  log10 reduction of 3.44 ± 0.75.
Testing of the clinical strains revealed fungicidal activity against C. parapsilosis in three of the four antisep-
tics: PVP-I (logR = 4.50 ± 0.49), and PHMB-B and OCT-D (the same and consistent results of  log10 reduction of 
4.63 ± 0.08) In contrast, the SOS at the same concentration of 80% showed a logR less than 4 (logR = 3.54 ± 0.56), 
similar to that observed for C. albicans, with no fungicidal activity. However, when we tested the SOS at 95% 
(optional condition according to the protocol), a logR of 4.35 ± 0.72 was determined for C. parapsilosis.
For the dermatophytes, the antiseptics PVP-I and OCT-D induced similar  log10 reductions for T. interdigitale, 
at logR = 4.29 ± 0.39, and T. rubrum induced  log10 reductions of logR = 4.18 ± 0.01 and logR = 4.18 ± 0.36, respec-
tively; fungicidal activity was observed for both antiseptics. The PHMB-B solution presented different antifungal 
potency depending on the dermatophyte species, with T. interdigitale being more susceptible than T. rubrum. 
In fact, fungicidal activity was observed against T. interdigitale, at logR = 4.40 ± 0.34, while for T. rubrum, no 
fungicidal effect was observed (logR < 4; 3.70 ± 0.53). Finally, the antiseptic SOS activity against dermatophytes 
Table 2.  Distribution of species identified in nail plate samples of Hospital Patients Group (HosPG). Data are 
n (%). *Some strains are colonization or contaminants.
n %
Dermatophytes
Trichophyton rubrum 27 37.5
Trichophyton interdigitale 11 15.3
Epidermophyton floccosum 1 1.4
Trichophyton violaceum 1 1.4
Subtotal 40 55.6
Nondermatophytes*
Aspergillus sp. 5 6.9
Penicillium sp. 5 6.9
Chaetomium sp. 4 5.6
Fusarium sp. 2 2.8
Alternaria sp. 2 2.8
Aspergillus niger 2 2.8
Acremonium sp. 1 1.4
Aspergillus fumigatus 1 1.4
Aspergillus penicillioides 1 1.4
Cladosporium sp. 1 1.4
Subtotal 24 33.3
Yeasts*
Candida parapsilosis 5 6.9
Candida albicans 1 1.4
Candida guilliermondii 1 1.4
Trichosporon mucoides 1 1.4
Subtotal 8 11.1
Total 72 100
Table 3.  Results of antiseptic solution testing for antifungal activity, presented in log reduction values. Values 
of  log10 reduction mean and standard deviation. In parentheses; n number of valid tests. PVP-I povidone-
iodine, PHMB-B polyhexamethylene biguanide-betaine, OCT-D octenidine dihydrochloride, SOS super-
oxidized solution. aTested compound at 80% (according to the protocol); bTested compound at 95%.
PVP-I PHMB-B OCT-D SOS
Aspergillus niger 3.10 ± 0.10 (n = 3) 3.10 ± 0.10 (n = 3) 3.10 ± 0.10 (n = 3) 3.10 ± 0.10 (n = 3)
Candida albicans 4.39 ± 0.12 (n = 2) 4.39 ± 0.12 (n = 2) 4.39 ± 0.12 (n = 2) 3.44 ± 0.75 (n = 3)
Candida parapsilosis 4.50 ± 0.49 (n = 4) 4.63 ± 0.08 (n = 2) 4.63 ± 0.08 (n = 2)
3.54 ± 0.56 (n = 5)a
4.35 ± 0.72 (n = 3)b
Trichophyton interdigitale 4.29 ± 0.39 (n = 2) 4.40 ± 0.34 (n = 3) 4.29 ± 0.39 (n = 2) 3.62 ± 0.68 (n = 4)
Trichophyton rubrum 4.18 ± 0.01 (n = 2) 3.70 ± 0.53 (n = 6) 4.18 ± 0.36 (n = 4) 3.23 ± 0.23 (n = 8)
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was variable, with no fungicidal activity; the logR values ranged between 3.62 ± 0.68 for T. interdigitale and 
3.23 ± 0.23 for T. rubrum.
Discussion
In the present study, OM prevalence, QOL, and the therapeutic regimen were studied, and the in vitro antifungal 
properties of antiseptics were evaluated in the most prevalent clinical species from the HosPG. Approximately 
half (53.3%) of the HosPG tested positive for OM, with T. rubrum being the most prevalent fungus, as found in 
previous  studies1,2,13,18,19.
The subjects reported self-care difficulties, need for a caregiver, and embarrassment as well as concerns about 
their feet. While no clear TRMS could be identified in most cases, the subjects presented characteristics associated 
with non-negligent management types. In the HomPG, OM was present in most of the subjects (82%). Several 
factors could account for the differences in the presence of dermatophyte fungi between the two samples in this 
study (40 dermatophyte positive/90; 44% in the HosSP and 41 dermatophyte positive/50; 82% in the HomPG). 
First, different tests were used to detect dermatophytes. The tests used in the HosPG (KOH + culture) (sensitivity 
61%/56%, specificity 99%/99%, predictive of positive value 96.3%/99.4%, predictive of negative value 55.9%/52%, 
respectively)20 have greater specificity but worse sensitivity than the immunochromatography test used in the 
HomPG, even though it does not allow the identification of dermatophytes (sensitivity 98%, specificity 78%, 
predictive of positive value 84.8%, predictive of negative value 97%, agreement rate 89.1%)21. It should be noted 
that the test used for the HomPG was specific for dermatophytes. Therefore, it is possible that other fungi may 
have been present in the samples analyzed but were not detected. Second, in the HosPG, we considered the 
conjugated positive data between the two methods (KOH + culture), while in the HomPG, who received a rapid 
test, all positive results (from weak to strong positives) were considered. Third, as foot hygiene conditions in the 
HomPG were worse than those in the HosPG, higher prevalence results were expected.
The limitations of our study include a small, number of participants which were included in the study, particu-
larly in the HomPG and the use of different diagnostic tests, and the absence of molecular methods in diagnosis. 
For the HosPG, the tests were able to be performed at the hospital’s laboratory; however, for the HomPG, a private 
laboratory would be necessary to perform the same tests. To avoid this, a quick diagnostic test was carried out 
on location, which was more easily accepted by Homeless people. In addition, the different ages of the popula-
tions and the homelessness condition may have affected the results. Also, only a limited number of strains were 
analyzed (representing the ones that were more prevalent in our samples) and therefore additional studies are 
required to determine if the susceptibility tests and conclusions are extensive to other species and strains. Last, 
it should also be considered that the diagnostic tests evaluated with culture and KOH were valid but are known 
to be inferior to PAS  staining20. This means that the prevalence rate reported here may be underestimated.
An in vitro antimicrobial study revealed that povidone-iodine and octenidine dihydrochloride presented 
fungicidal activity against clinical strains of T. rubrum and T. interdigitale, as well against C. parapsilosis and 
C. albicans. Considering that the most common species isolated from OM are  dermatophytes6,10, and in the 
present study, they were T. rubrum and T. interdigitale, as well as the yeasts C. albicans and C. parapsilosis, it can 
be concluded that PVP-I and OCT-D have broad spectrums to treat or prevent OM due to the most common 
fungal agents. Fungi in the genus Aspergillus may also be involved in OM, although this is  rare19. According to 
the standard used, none of the studied antiseptics had fungicidal activity against A. niger.
The antiseptic solution PVP-I has already demonstrated efficacy in the skin and mucous membranes against 
viruses and bacteria, with microbial inactivation greater than 99.99%22–24. Additionally, the OCT-D solution 
has demonstrated good efficacy against skin microflora in multiple  studies22,24,25, with stronger activity against 
Staphylococcus epidermidis and weaker activity against Escherichia coli and C. albicans22. Furthermore, this solu-
tion seems to represent a well-tolerated, safe and efficacious therapeutic choice for the treatment of Pseudomonas 
nail plate  infection26. In our study, we verified identical reductions in fungal clinical strains by both antiseptic 
solutions.
PHMB has demonstrated its effectiveness against several  microorganisms11,27,28. In textile tests, PHMB dem-
onstrated good efficacy against T. rubrum, and the SOS demonstrated good efficacy against T. mentagrophytes29. 
However, a different result was observed in our study; PHMB had fungicidal activity (logR > 4) against T. inter-
digitale but not against T. rubrum (logR < 4). For T. rubrum, although a decrease in CFUs was observed, no 
fungicidal activity was found according to the standard test. While Hammer et al. (2011) reported activity of the 
SOS against T. rubrum29 using antimicrobial textiles, for our standard test, no fungicidal activity was observed 
toward dermatophytes and yeasts cells. Nevertheless, for both antiseptic solutions, it should be noted that we were 
comparing different tests. In the present study, we observed that the SOS activity decreased over time, suggesting 
a loss of activity after opening of the packaging. This was also identified in studies by Rossi-Fedele et al., who 
reported that stability was affected by storage conditions and exposure to  light30. Additional testing with a new 
sample of SOS revealed stronger activity, and when we tested the older sample at 95%, we observed an increase 
in activity. However, this consideration could limit the use of this solution if it remains open for long periods.
OM has a worldwide impact due to its chronicity, with high resistance to treatments and frequent 
 recurrence2,31,32. OM reduces QOL, triggering physical, mental and social problems affecting daily  activities33. 
In patients with risk factors, it can cause severe cases of infection, with the need for differentiated health care, 
overloading health care services and increasing the cost of  care4,34. Our results indicated that OM reduced the 
quality of life of patients; they also reported that they were concerned about the state of their feet and that they 
had non-negligent therapeutic regimen management styles. Therefore, our findings suggest that the potential of 
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Finally, a somewhat similar therapeutic has been proposed in a recent patent application involving a petro-
latum-based solution to treat  OM35.
Conclusion
The present study indicates that OM affected the QOL of two different vulnerable populations and that these 
subjects reported being embarrassed and concerned about their feet. The TRMS of the Hospital patient sample 
revealed characteristics related to non-negligent management styles. In vitro antimicrobial evaluations of anti-
septics revealed antifungal properties toward cells of the clinical fungi. These results support the need for further 
studies on the use of antiseptics in the treatment of OM.
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